Search | BIO

Home

Search

682 Results Found

Here’s What You Need to Know as Capitol Hill Talks Prescription Drug Costs

Drug prices will be in the spotlight this week as committees in both the House and Senate are set to hold hearings on the cost of prescription drugs. Since this is the first time the new Congress will take a close look at this important issue, here are four facts we encourage policymakers to keep…

Happy 91st Birthday Senator Bayh!

At its best, government enables citizens to flourish socially and economically. Above and beyond the basic services we all expect, responsible governments empower citizens to provide for themselves in a rapidly evolving world. Through Senator Birch Bayh’s long career of public service, he led a…

Despite Administration’s “Sky-High Rhetoric,” Importing Foreign Price Controls Will Harm Innovation and Patient Access

In October of 2018, the Trump Administration outlined a proposal that would import foreign price controls for medicines covered under Medicare Part B. Despite warnings from BIO and dozens of other industry experts and patient advocates, the administration continues to defend its flawed plan and…

The Right Way to Address Prescription Drug Costs

Writing for STAT News, BIO’s President and CEO Jim Greenwood teamed up with Bay City Capital’s David Beier to outline for policymakers the best approach for tackling the affordability of prescription drugs. “As policy professionals from different sides of the aisle, we believe there is a right way…

BIO Comments on Objectives for U.S. Japan Trade Agreement

BIO supports the U.S. Trade Representative’s (USTR) negotiations with the Government of Japan as an opportunity to grow U.S. exports and create U.S. jobs. We would strongly urge the U.S. government to build on the recent U.S.-Mexico-Canada agreement and that the agreement comprehensively addresses…

The Administration’s Orwellian Defense of Importing Foreign Price Controls

The Trump administration is out with a new blog post defending its plan to adopt foreign price controls for medicines covered under Medicare Part B. The blog was written in the wake of growing backlash from free-market thought leaders who are challenging the administration’s draconian proposal. …

Greenwood Talks Innovation, Drug Pricing, and the Midterm Elections on ForbesBooks Radio

During the Forbes Healthcare Summit, BIO CEO Jim Greenwood joined Gregg Stebben, host of ForbesBooks Radio, for a discussion about innovation taking place in the biopharma industry, the cost and value of prescription medicines and how the recent midterm elections may impact the drug pricing debate…

Think the Drug-Pricing debate addresses Patient Costs? Think again.

Writing for The Hill, BIO President and CEO Jim Greenwood tackled the drug pricing debate in Washington and touched on President Trump’s proposals for lowering drug prices. On the Administration’s recent International Pricing Index (IPI), which would move from a market-based payment formula for…

Another Year, Another Misleading Insurance Company Report

Once again, Blue Cross Blue Shield is out with a report attempting to stoke fear and confusion about prescription drug costs. And once again (because we’ve chronicled it before) what the major insurance company has to say is contradicted by its own pharmacy benefits manager. These drug cost…

Patient Advocates Sounding the Alarm Over Fail First

The Centers for Medicare & Medicaid Services (CMS) has reversed a long-standing policy allowing Medicare Advantage plans to impose “step therapy” requirements for physician-administered drugs – also known as Medicare Part B. More accurately described as “fail first,” this dangerous policy will…